AKT1 and non-small cell lung carcinoma: In summary, pre-clinical studies present compelling evidence that targeting AKT1 is an effective strategy to impair lung cancer development and future clinical trials on NSCLC may benefit by incorporating AKT1 inhibitors into their therapeutic strategy.